Publications by authors named "Shigeru Mikami"

Claim this Profile
A
Association Between Laboratory Values and Covert Hepatic Encephalopathy in Patients with Liver Cirrhosis: A Multicenter, Retrospective Study.
Kaori Koyano, Masanori Atsukawa, Akihito Tsubota, Chisa Kondo, Takao Miwa, Shigeru Mikami

J Clin Med· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kinetics of the hepatitis B core-related antigen and treatment responses in chronic hepatitis B patients treated with tenofovir alafenamide.
Norio Itokawa, Masanori Atsukawa, Akihito Tsubota, Toru Ishikawa, Hidenori Toyoda, Shigeru Mikami

Hepatol Res· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Distribution of Fibrosis-4 index and vibration-controlled transient elastography-derived liver stiffness measurement for patients with metabolic dysfunction-associated steatotic liver disease in health check-up.
Yuji Ogawa, Wataru Tomeno, Yasushi Imamura, Masaru Baba, Takato Ueno, Shigeru Mikami

Hepatol Res· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ALBI score predicts morphological changes in esophageal varices following direct-acting antiviral-induced sustained virological response in patients with liver cirrhosis.
Masanori Atsukawa, Akihito Tsubota, Chisa Kondo, Hidenori Toyoda, Koichi Takaguchi, Shigeru Mikami

J Gastroenterol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of six hepatocellular carcinoma prediction models in Japanese patients after sustained virologic response undergoing rigorous surveillance for hepatocellular carcinoma.
Hidenori Toyoda, Toshifumi Tada, Haruki Uojima, Akito Nozaki, Makoto Chuma, Shigeru Mikami

J Gastroenterol Hepatol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regional Differences in Clinical Presentation and Prognosis of Patients With Post-Sustained Virologic Response Hepatocellular Carcinoma.
Hidenori Toyoda, Mounika Kanneganti, Jonathan Melendez-Torres, Neehar D Parikh, Prasun K Jalal, Shigeru Mikami

Clin Gastroenterol Hepatol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk factors for portopulmonary hypertension in patients with cirrhosis: a prospective, multicenter study.
Masanori Atsukawa, Akihito Tsubota, Chisa Kondo, Kaori-Shioda Koyano, Toru Ishikawa, Shigeru Mikami

Hepatol Int· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antifibrotic effect and long-term outcome of SGLT2 inhibitors in patients with NAFLD complicated by diabetes mellitus.
Taeang Arai, Masanori Atsukawa, Akihito Tsubota, Shigeru Mikami, Uojima Haruki

Hepatol Commun· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Misunderstanding of hepatitis C virus (HCV) infection status by non-specialized medical doctors in patients who achieved sustained virologic response to anti-HCV therapy.
Hidenori Toyoda, Satoshi Yasuda, Akio Moriya, Ei Itobayashi, Haruki Uojima, Shigeru Mikami

J Infect Chemother· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
International multicenter validation of GES score for HCC risk stratification in chronic hepatitis C patients.
Gamal Shiha, Reham Soliman, Nabiel N H Mikhail, Fabrice Carrat, Jessica Azzi, Shigeru Mikami

J Viral Hepat· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mac-2-binding protein glycan isomer predicts all malignancies after sustained virological response in chronic hepatitis C.
Kazuhito Kawata, Masanori Atsukawa, Kazuyoshi Ohta, Takeshi Chida, Hidenao Noritake, Shigeru Mikami

Hepatol Commun· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Shorter pruritus period and milder disease stage are associated with response to nalfurafine hydrochloride in patients with chronic liver disease.
Tadamichi Kawano, Masanori Atsukawa, Akihito Tsubota, Noritomo Shimada, Hidenori Toyoda, Shigeru Mikami

Sci Rep· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Impact of Cirrhosis and History of Hepatocellular Carcinoma on All-Cause Mortality After Eradication of Hepatitis C Virus in Patients With Chronic Hepatitis C.
Hidenori Toyoda, Masanori Atsukawa, Haruki Uojima, Akito Nozaki, Koichi Takaguchi, Shigeru Mikami

Gastro Hep Adv· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time-course changes in liver functional reserve after successful sofosbuvir/velpatasvir treatment in patients with decompensated cirrhosis.
Masanori Atsukawa, Akihito Tsubota, Chisa Kondo, Hidenori Toyoda, Makoto Nakamuta, Shigeru Mikami

Hepatol Res· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics and Prognosis of Hepatocellular Carcinoma After Sustained Virologic Response.
Hidenori Toyoda, Atsushi Hiraoka, Haruki Uojima, Akito Nozaki, Noritomo Shimada, Shigeru Mikami

Hepatol Commun· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Virological Efficacy and Safety of Ledipasvir and Sofosbuvir in Patients with Chronic Hepatitis C Virus Genotype 2 Infection: A Multicenter Study.
Toshifumi Tada, Takashi Kumada, Hiroaki Okushin, Joji Tani, Koichi Takaguchi, Shigeru Mikami

Infect Dis Ther· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data.
Taeang Arai, Masanori Atsukawa, Akihito Tsubota, Shigeru Mikami, Hiroki Ono

Ther Adv Endocrinol Metab· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequential therapy from entecavir to tenofovir alafenamide continuous entecavir monotherapy for patients with chronic hepatitis B.
Norio Itokawa, Masanori Atsukawa, Akihito Tsubota, Koichi Takaguchi, Makoto Nakamuta, Shigeru Mikami

JGH Open· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Clinical Application of 12-Week Sofosbuvir/Velpatasvir Treatment for Decompensated Cirrhotic Patients with Genotype 1 and 2: A Prospective, Multicenter Study.
Masanori Atsukawa, Akihito Tsubota, Chisa Kondo, Hidenori Toyoda, Makoto Nakamuta, Shigeru Mikami

Infect Dis Ther· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Marked heterogeneity in the diagnosis of compensated cirrhosis of patients with chronic hepatitis C virus infection in a real-world setting: A large, multicenter study from Japan.
Hidenori Toyoda, Masanori Atsukawa, Tsunamasa Watanabe, Makoto Nakamuta, Haruki Uojima, Shigeru Mikami

J Gastroenterol Hepatol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world experience of 12-week direct-acting antiviral regimen of glecaprevir and pibrentasvir in patients with chronic hepatitis C virus infection.
Hidenori Toyoda, Masanori Atsukawa, Tsunamasa Watanabe, Makoto Nakamuta, Haruki Uojima, Shigeru Mikami

J Gastroenterol Hepatol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter study.
Akito Nozaki, Masanori Atsukawa, Chisa Kondo, Hidenori Toyoda, Makoto Chuma, Shigeru Mikami

Hepatol Int· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of 8-week glecaprevir/pibrentasvir treatment in direct-acting antiviral-naïve noncirrhotic HCV genotype 1 and 2infected patients in a real-world setting in Japan.
Hiroki Ikeda, Tsunamasa Watanabe, Masanori Atsukawa, Hidenori Toyoda, Koichi Takaguchi, Shigeru Mikami

J Viral Hepat· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trends and Efficacy of Interferon-Free Anti-hepatitis C Virus Therapy in the Region of High Prevalence of Elderly Patients, Cirrhosis, and Hepatocellular Carcinoma: A Real-World, Nationwide, Multicenter Study of 10 688 Patients in Japan.
Hidenori Toyoda, Masanori Atsukawa, Haruki Uojima, Akito Nozaki, Hideyuki Tamai, Shigeru Mikami

Open Forum Infect Dis· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
J
Japanese patient preferences regarding intermediate to advanced hepatocellular carcinoma treatments.
Tetsuhiro Chiba, Atsushi Hiraoka, Shigeru Mikami, Masami Shinozaki, Yukio Osaki

Patient Prefer Adherence· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis